The approval, granted under the Federal Food, Drug, and Cosmetic Act, covers the 10 mg/2 mL (5 mg/mL) dosage format. These prefilled syringes are indicated for managing anxiety disorders and providing short-term relief from associated symptoms. By entering this space, Lupin leverages its existing manufacturing infrastructure to capture a share of the market previously held by the reference listed drug.

Data from IQVIA MAT for May 2026 highlights the significant commercial scale of this segment, with annual sales reaching nearly $78 million. For Lupin, this authorization reinforces its strategy of expanding its generic portfolio within the United States, adding to a broad therapeutic footprint that spans cardiovascular, respiratory, and central nervous system treatments. The company currently operates 15 manufacturing sites worldwide to support its global distribution network.